GlycoMimetics

About:

GlycoMimetics is a biopharmaceutical company designing and developing small molecule therapeutics to treat various cancers.

Website: http://www.glycomimetics.com

Top Investors: New Enterprise Associates, Novartis Venture Fund, Cowen Investment Management, Alliance Technology Ventures, PTV Healthcare Capital

Description:

GlycoMimetics, Inc., a biopharmaceutical company, engages in the design and development of small molecule therapeutics to mimic the functions of bioactive carbohydrates. Its products include GMI-1070, a synthetic glycomimetic molecule designed to inhibit selectin types, such as E, P, and L-selectin; and GMI-1051, a small molecular weight compound for the treatment or prevention of infections caused by pseudomonas aeruginosa. The company was founded in 2003 and is based in Gaithersburg, Maryland.